Home › Bayer: FDA will speed review of 2 respiratory...
 

Keywords :   


Bayer: FDA will speed review of 2 respiratory...

2014-11-25 04:15:44| Chemicals - Topix.net

Two medicines Bayer HealthCare Pharmaceuticals Inc. is testing for respiratory disorders will get priority review by U.S. regulators and other benefits under a 2012 program to boost development of new antibiotics. Bayer HealthCare, based in Whippany, New Jersey, said Monday the Food and Drug Administration has designated two of its experimental treatments as qualified infectious disease products.

Tags: review speed respiratory bayer

Category:Chemicals

Latest from this category

All news
09.05Maryland Adopts PaintCare Program
09.05Asian Paints Reports 4Q, Full FY 2024 Results
08.05Teknos\' Sustainability in 2023: Making the World Last Longer
08.05Hempel Enters Strategic Partnership with CVC
08.05California Sports Surfaces Offers New Contractor ProProgram
08.05Sheboygan Paint Company Announces Promotion
07.05Trust in Paint Brand and Retailer Now Major Indicator of Customer Satisfaction, J.D. Power Finds
07.05Interpon Launches Structura Powder Coating Collection in North America
Chemicals »
09.05Scalstrm and EZDRM partner on video content security
09.05Appvion launches EarthChem sustainable direct thermal portfolio
09.05Glatfelter Reports Financial Results
09.05Maryland Adopts PaintCare Program
09.05Society of Cosmetic Chemists Intermountain West to Host Healthy Bite Oral Care Symposium
09.05A.Celli and Akinal Tekstil Collaborate on Line Installation
09.05Record levels of shoplifting show signs of falling
09.05National Advertising Division Recommends Amyris Clean Beauty Modify Claim
More »